The advisors on Granite Bio’s financing rounds
Walder Wyss and Vischer are amongst the firms involved in Granite Bio’s Series A and Series B financing round.
In particular Vischer advised Forbion and Sanofi Ventures on all legal issues related to their role as lead investors in a USD 70m Series B financing round, while Walder Wyss advised founding investors Versant Ventures and Novartis Venture Fund in a USD 30m Series A financing round.
The context
Headquartered in Basel, Granite Bio is a clinical-stage immunology company which specialises in the development of antibodies targeting the root causes of different inflammatory, autoimmune and fibrotic conditions.
The company raised a combined USD 100m in funding between a USD 30m Series A financing round led by founding investors Versant Ventures and Novartis Venture Fund, and a USD 70m Series B financing round led by Forbion, a venture capital firm with offices in The Netherlands, Germany and USA, and Sanofi Ventures, the corporate venture capital arm of Sanofi.
The Vischer team
The Vischer corporate/M&A team featured partner Christian Wyss (pictured above), managing associate Luzius Zumstein, senior associate Pauline Pfirter and associate Alessandro L. Meyer.
The Walder Wyss team
The Walder Wyss team included partners Robert von Rosen (corporate/M&A and venture capital, pictured left) and Alexander Gutmans (corporate/M&A and venture capital, pictured right), as well as managing associate Karina Tschon (corporate/M&A and venture capital) and senior associate Lucas Maurer (corporate/M&A).
